Study finds that new, expensive anti-psychotics were no better than the older drugs

A major study by the National Institute of Mental Health performed in 2005 found that Zyprexa and Risperdal were no more effective than the existing anti-psychotics, which were far cheaper.    The study has now been confirmed by another NIMH study involving 116 subjects. Treatment outcomes were not improved with the new drugs, they cost far more, and they also cause more troubling side-effects, including significant weight gain and troubling changes in cholesterol and insulin levels.

These new drugs were heavily promoted and were widely prescribed before adequate  comparative testing was performed.  No one benefited except the pharmaceutical manufacturers with their aggressive marketing strategies and exorbitant prices.